Recovery% ± SD
Sample Reported methodsc Proposed methods
  Method A Method B Method C
Factive Tablets        
X ± SDa 100.08 ± 0.56 99.84 ± 0.69 100.20 ± 0.72 99.65 ± 0.48
t-Valueb   0.60 0.29 1.30
F-Valueb   1.52 1.65 1.36
Flobiotic tablets        
X ± SDa 99.94 ± 0.68 100.15 ± 0.82 99.70 ± 0.47 99.80 ± 0.60
t-Valueb   0.44 0.65 0.35
F-Valueb   1.45 2.09 0.77
GemiQue tablets        
X ± SDa 99.85 ± 0.49 99.45 ± 0.65 100.10 ± 0.53 99.50 ± 0.37
t-Valueb   1.10 0.77 1.27
F-Valueb   1.76 1.17 1.75
Avelox® tablets        
X ± SDa 99.03 ± 0.97 99.60 ± 1.16 99.70 ± 0.84 99.40 ± 0.76
t-Valueb   0.84 1.17 0.67
F-Valueb   1.43 1.33 1.63
Moxiflox tablets        
X ± SDa 99.34 ± 0.34 99.54 ± 0.42 99.58 ± 0.50 99.70 ± 0.48
t-Valueb   0.83 0.89 1.37
F-Valueb   1.53 2.16 1.99
Moxifloxacin tablets        
X ± SDa 99.94 ± 0.92 99.90 ± 0.88 100.20 ± 1.15 100.05 ± 1.20
t-Valueb   0.07 0.39 0.16
F-Valueb   1.09 1.56 1.70
aMean for six independent analyses.
bTheoretical values for t and F-values at five degree of freedom and 95% confidence limit are (t=2.57) and (F=5.05).
cReference spectrophotometric methods for GMF [39] and MXF [50].
Table 5: Application of the proposed methods for the determination of GMF and MXF in their pharmaceutical preparations.